2. Academic Validation
  3. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis

Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis

  • Neurodegener Dis Manag. 2019 Feb;9(1):5-23. doi: 10.2217/nmt-2018-0033.
Arnt V Kristen 1 2,  Senda Ajroud-Driss 3,  Isabel Conceição 4,  Peter Gorevic 5,  Theodoros Kyriakides 6,  Laura Obici 7
Affiliations

Affiliations

  • 1 Department of Cardiology, University of Heidelberg, Heidelberg, D-69120, Germany.
  • 2 Cardiovascular Center Darmstadt, Darmstadt, 64287, Germany.
  • 3 Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA.
  • 4 Centro Hospitalar Lisboa Norte, Hospital de Santa Maria, Universidade de Lisboa, Faculdade de Medicina, 1649-028, Portugal.
  • 5 Department of Medicine, Mount Sinai Medical Center, New York, NY 10029, USA.
  • 6 The Cyprus Institute of Neurology & Genetics, Nicosia, 1683, Cyprus.
  • 7 Amyloidosis Research & Treatment Centre, Fondazione IRCCS Policlinico San Matteo, Pavia, 27100, Italy.
PMID: 30480471 DOI: 10.2217/nmt-2018-0033
Abstract

Hereditary transthyretin-mediated amyloidosis is a rapidly progressive, heterogeneous disease caused by the accumulation of misfolded transthyretin protein as amyloid fibrils at multiple sites, and is characterized by peripheral sensorimotor neuropathy, autonomic neuropathy and/or cardiomyopathy. Current treatment options have limited efficacy and often do not prevent disease progression. Patisiran is a novel RNA interference therapeutic that specifically reduces production of both wild-type and mutant transthyretin protein. In Phase II, III and long-term extension studies in patients with hereditary transthyretin-mediated amyloidosis, patisiran has consistently slowed or improved progression of neuropathy. In addition, the Phase III trial demonstrated significant improvements in quality of life measures and Indicators of cardiomyopathy. Here, we highlight efficacy and safety data from the patisiran clinical trial programme.

Keywords

cardiomyopathy; clinical trials; disease-modifying therapy; hATTR amyloidosis; patisiran; polyneuropathy.

Figures
Products